ATN001
Pre-clinical- Indications
- Solid tumors
Company intelligence / Profile preview
Atheon Bio
Bundang-gu, Gyeonggi-do, South Korealinkedin.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
Animal experimentation confirmed synergistic effects when ATN001 is combined with immune checkpoint inhibitors on cancerous vessels[1]
- Therapeutic areas
- Oncology
- Modalities
- Antibody drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
HLB Life Sciences (exploring combination of Rivoceranib with ATN001)[1]
Beyond the preview
Go deeper on Atheon Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atheon Bio.